|
Ballantyne 2013
|
US
|
177
|
44.6
|
57.5
|
28.2
|
12
|
166.2
|
No stain used
|
40, 80, or 120 mg daily
|
|
Gutierrez 2014
|
US
|
60
|
38.3
|
55.7
|
29.9
|
12
|
126.8
|
No stain used
|
180 mg daily
|
|
Thompson 2015
|
US
|
56
|
50.0
|
63.5
|
29.7
|
12
|
179.05
|
Statin intolerant
|
120 mg, 180 mg, or 240 mg
|
|
Ballantyne 2016
|
US
|
133
|
59.4
|
57.3
|
30.3
|
12
|
135.6
|
Stable statin background therapy
|
180 mg daily
|
|
Thompson 2016
|
US
|
149
|
71.1
|
59.7
|
29.7
|
12
|
163.9
|
With or without statin intolerant
|
120 mg or 180 mg
|
|
Ballantyne 2018
|
US
|
269
|
61.3
|
63.8
|
29.8
|
12
|
127.6
|
Statin intolerance
|
180 mg daily
|
|
Laufs 2019
|
Germany
|
345
|
50.4
|
65.2
|
30.3
|
24
|
157.6
|
Statin intolerance
|
180 mg daily
|
|
Ray 2019
|
UK
|
2230
|
27.0
|
66.1
|
NR
|
52
|
103.2
|
Maximally tolerated statin therapy
|
180 mg daily
|
|
Ballantyne 2019
|
US
|
129
|
50.4
|
65.1
|
30.6
|
12
|
148.08
|
Maximally tolerated statin therapy
|
180 mg daily
|
|
Goldberg 2019
|
US
|
779
|
36.3
|
64.3
|
30.2
|
52
|
120.4
|
Maximally tolerated statin therapy
|
180 mg daily
|
|
Lalwani 2019
|
US
|
64
|
48.4
|
58.0
|
31.0
|
4
|
76.4
|
High-intensity statin background therapy
|
180 mg daily
|
